Literature DB >> 27074261

Highlights from the 2015 North American Cystic Fibrosis Conference.

Edith T Zemanick1, Thida Ong2, Cori L Daines3, Elisabeth P Dellon4, Marianne S Muhlebach4, Charles R Esther4.   

Abstract

The 29th Annual North American Cystic Fibrosis Conference was held in Phoenix, Arizona on October 8-10, 2015. Abstracts were published in a supplement to Pediatric Pulmonology.(1) In this review, we summarize presentations in several of the topic areas addressed at the conference. Our goal is to provide an overview of presentations with relevance to emerging or changing concepts in several areas rather than a comprehensive review. Citations from the conference are by first author and abstract number or symposium number, as designated in the supplement. Pediatr Pulmonol. 2016;51:650-657.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  CFTR modulators; antibiotic therapy; clinical trials; cystic fibrosis; personalized medicine; quality improvement

Mesh：

Substances：

Year:  2016        PMID： 27074261      PMCID： PMC5935494          DOI： 10.1002/ppul.23441

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN： 1099-0496


  29 in total

1.  CF healthcare workers feel unprepared in providing suitable end of life care and desire more education: Results of a nationwide survey.

Authors:  Jessica Goggin; Rubin I Cohen
Journal:  J Cyst Fibros       Date:  2015-09-08       Impact factor: 5.482

2.  Experience of care from the perspective of individuals with cystic fibrosis and families: Results from 70 CF Foundation accredited programs in the USA.

Authors:  Karen Homa; Kathryn A Sabadosa; Laura C Marrow; Bruce C Marshall
Journal:  J Cyst Fibros       Date:  2015-01-30       Impact factor: 5.482

Review 3.  Key findings of the US Cystic Fibrosis Foundation's clinical practice benchmarking project.

Authors:  Michael P Boyle; Kathryn A Sabadosa; Hebe B Quinton; Bruce C Marshall; Michael S Schechter
Journal:  BMJ Qual Saf       Date:  2014-04       Impact factor: 7.035

4.  Depression, illness severity, and healthcare utilization in cystic fibrosis.

Authors:  Carolyn Snell; Serena Fernandes; I Simona Bujoreanu; Georgina Garcia
Journal:  Pediatr Pulmonol       Date:  2014-03-12

5.  Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.

Authors:  Xiaojiao Xue; Venkateshwar Mutyam; Liping Tang; Silpak Biswas; Ming Du; Laura A Jackson; Yanying Dai; Valery Belakhov; Moran Shalev; Fuquan Chen; Jochen Schacht; Robert J Bridges; Timor Baasov; Jeong Hong; David M Bedwell; Steven M Rowe
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

6.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

7.  Cystic fibrosis (CF) care through the patients' eyes - a nationwide survey on experience and satisfaction with services using a disease-specific questionnaire.

Authors:  Gratiana Steinkamp; Katja Stahl; Helmut Ellemunter; Eberhard Heuer; Silke van Koningsbruggen-Rietschel; Melanie Busche; Wilhelm Bremer; Carsten Schwarz
Journal:  Respir Med       Date:  2014-12-06       Impact factor: 3.415

Review 8.  Tackling the increasing complexity of CF care.

Authors:  Gregory S Sawicki; Christopher H Goss
Journal:  Pediatr Pulmonol       Date:  2015-10

9.  International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety.

Authors:  Alexandra L Quittner; Janice Abbott; Anna M Georgiopoulos; Lutz Goldbeck; Beth Smith; Sarah E Hempstead; Bruce Marshall; Kathryn A Sabadosa; Stuart Elborn
Journal:  Thorax       Date:  2015-10-09       Impact factor: 9.139

10.  SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.

Authors:  Greg Ogrinc; Louise Davies; Daisy Goodman; Paul Batalden; Frank Davidoff; David Stevens
Journal:  BMJ Qual Saf       Date:  2015-09-14       Impact factor: 7.035
View more
  1 in total

Review 1.  Highlights from the 2016 North American Cystic Fibrosis Conference.

Authors:  Edith T Zemanick; Cori L Daines; Elisabeth P Dellon; Charles R Esther; BreAnna Kinghorn; Thida Ong; Marianne S Muhlebach
Journal:  Pediatr Pulmonol       Date:  2017-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.